EMIL (Epigenetic Marker Ipomethylated for Acute Promyelocytic Leukemia) originates from the economic and scientific valorization of patent EP3458607, which concerns the use of an epigenetic signature for prognostic and/or diagnostic applications in the early assessment of Acute Promyelocytic Leukemia (APL). … Read More
Epi Blog
Epi Blog
Hypoxia-Regulated miRNAs in Human Mesenchymal Stem Cells: Exploring the Regulatory Effects in Ischemic Disorders
di Carmela Dell’Aversana — Permanent full researcher, at IEOS – CNR – ITALY — Human mesenchymal/stromal stem cells (hMSC) are the most promising cell source for adult cell therapies in regenerative medicine. Many clinical trials have reported the use of … Read More
3-Chloro- N’-(2-hydroxybenzylidene) benzohydrazide: An LSD1-Selective Inhibitor and Iron-Chelating Agent for Anticancer Therapy
di Federica Sarno — Post-doc position of University of Study Luigi Vanvitelli — Despite the discovery and development of novel therapies, cancer is still a leading cause of death worldwide. In order to grow, tumor cells require large quantities of … Read More
Discovery of novel tetrahydrobenzo[b]thiophene-3-carbonitriles as histone deacetylase inhibitors
di Lucia Altucci — Full Professor of General Pathology, University of Campania Luigi Vanvitelli, IT — The discovery and development of isoform-selective histone deacetylase (HDAC) inhibitor is a challenging task because of the sequence homology among HDAC enzymes. In the … Read More